A case study of personalized therapy for osteosarcoma

Pediatric Blood and Cancer

Volumn 60, Issue 8, 2013, Pages 1313-1319

  Davis, Lara E ^a   Hofmann, Nicolle E ^a   Li, Guangheng ^a   Huang, Elaine T ^a   Loriaux, Marc M ^a   Bracha, Shay ^b   Helfand, Stuart C ^b   Mata, John E ^b   Marley, Kevin ^b   Mansoor, Atiya ^a   Tyner, Jeffrey W ^a   Abraham, Jinu ^a   Séguin, Bernard ^b   Keller, Charles ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Canine; Dasatinib; Osteosarcoma; Tyrosine kinase inhibitor

Indexed keywords

DASATINIB; FLAVOPIRIDOL; MIDOSTAURIN; ONDANSETRON; PONATINIB;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CASE STUDY; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SCREENING; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; OSTEOSARCOMA; PERSONALIZED MEDICINE; PRIORITY JOURNAL;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; DOG DISEASES; DOGS; OSTEOSARCOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES; TIME FACTORS;

EID: 84875798679     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24512     Document Type: Article

References (13)

1. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. Based on November 2009 SEER data submission, posted to the SEER web site, 2010. National Cancer Institute .
2. Fox E, Aplenc R, Bagatell R, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-Vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 2010; 28:5174-5181.
3. Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28:2839-2846.
4. Kurzrock R, Patnaik A, Aisner J, et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010; 16:2458-2465.
5. Withrow SJ, Wilkins RM. Cross talk from pets to people: Translational osteosarcoma treatments. ILAR J 2010; 51:208-213.
6. Hosoyama T, Nishijo K, Prajapati SI, et al. Rb1 gene inactivation expands satellite cell and postnatal myoblast pools. J Biol Chem 2011; 286:19556-19564.
7. Overholtzer M, Rao PH, Favis R, et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci USA 2003; 100:11547-11552.
8. Benassi MS, Molendini L, Gamberi G, et al. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer 1999; 84:489-493.
9. Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: A report from the children's oncology group phase I consortium. J Clin Oncol 2011; 29:839-844.
10. Bullock JM, Noory C, Men A, et al. Clinical pharmacology review: Spycel, dasatinib [Application no. 21-986]. U.S. Food and Drug Administration, Center for Drug Evaluation and Research; 2006.
11. Liu X, Ory V, Chapman S, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 2012; 180:599-607.
12. Davis LE, Mori M, Keller C. Personalized cancer care: Opportunities and challenges in pediatric neuro-oncology. Pediatr Blood Cancer 2012; 59:1-2.
13. Liptak JM, Dernell WS, Farese JP, et al. Musculoskeletal tumors. In: Kudnig ST, Seguin B, editors. Veterinary surgical oncology. Ames: Wiley-Blackwell; 2012. pp 491-568.